Frostyyy的个人主页 - 老虎社区

Frostyyy

暂无个人介绍

IP属地：未知

10关注

3粉丝

0主题

0勋章

2021-11-16

Pls drop so that i can buy more

抱歉，原内容已删除

2021-11-02

Go go go!!!

Novavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote>

2021-11-03

To the moon!!

Some meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote>

2021-10-20

Gg overpromise again

Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>

2021-12-02

Not the time yet

抱歉，原内容已删除

2021-10-19

Very good

抱歉，原内容已删除

2021-10-06

why sell???

抱歉，原内容已删除

2021-12-07

EV to the moon

抱歉，原内容已删除

2021-10-22

$AMD(AMD)$ up up up!!!

2021-08-16

loving the reds

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3581131361771943","uuid":"3581131361771943","gmtCreate":1618276998852,"gmtModify":1618276998852,"name":"Frostyyy","pinyin":"frostyyy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":10,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":606853487,"gmtCreate":1638861086065,"gmtModify":1638861086179,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"EV to the moon","listText":"EV to the moon","text":"EV to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606853487","repostId":"2189682681","repostType":4,"isVote":1,"tweetType":1,"viewCount":3396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603619690,"gmtCreate":1638404643257,"gmtModify":1638404643467,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Not the time yet","listText":"Not the time yet","text":"Not the time yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603619690","repostId":"2188690505","repostType":4,"isVote":1,"tweetType":1,"viewCount":3551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871185699,"gmtCreate":1637037132655,"gmtModify":1637037302349,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Pls drop so that i can buy more","listText":"Pls drop so that i can buy more","text":"Pls drop so that i can buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/871185699","repostId":"1160740007","repostType":4,"isVote":1,"tweetType":1,"viewCount":2988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841543109,"gmtCreate":1635928603322,"gmtModify":1635928603322,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"To the moon!!&nbsp;","listText":"To the moon!!&nbsp;","text":"To the moon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841543109","repostId":"1178338626","repostType":4,"repost":{"id":"1178338626","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635928227,"share":"https://www.laohu8.com/m/news/1178338626?lang=zh_CN&edition=full","pubTime":"2021-11-03 16:30","market":"us","language":"en","title":"Some meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178338626","media":"Tiger Newspress","summary":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Bran","content":"<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p><p><blockquote>一些模因股票在盘前交易中飙升。Bed Bath&amp;Beyond, R.R.Donnelley&amp;Sons、Naked Brand、Koss、Express、AMC、游戏驿站和黑莓股价飙升4%至62%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p><p><blockquote><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">贝德柏士比昂公司</a>这家家居用品零售商宣布的消息可能引发了所谓的轧空，做空该股的对冲基金被迫回购股票以减少损失。</blockquote></p><p> Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p><p><blockquote>商业印刷公司。据知情人士透露，Donnelley&amp;Sons Co.即将达成协议，以略高于20亿美元（包括债务）的价格将自己出售给一家私募股权公司。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-03 16:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p><p><blockquote>一些模因股票在盘前交易中飙升。Bed Bath&amp;Beyond, R.R.Donnelley&amp;Sons、Naked Brand、Koss、Express、AMC、游戏驿站和黑莓股价飙升4%至62%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p><p><blockquote><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">贝德柏士比昂公司</a>这家家居用品零售商宣布的消息可能引发了所谓的轧空，做空该股的对冲基金被迫回购股票以减少损失。</blockquote></p><p> Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p><p><blockquote>商业印刷公司。据知情人士透露，Donnelley&amp;Sons Co.即将达成协议，以略高于20亿美元（包括债务）的价格将自己出售给一家私募股权公司。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXPR":"Express, Inc.","AMC":"AMC院线","BBBY":"Bed Bath & Beyond, Inc.","BB":"黑莓","KOSS":"高斯电子","RRD":"当纳利","GME":"游戏驿站"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178338626","content_text":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Brand,Koss,Express,AMC,GameStop and BlackBerry soared between 4% and 62%.\n\nBed Bath & Beyond,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.\nCommercial-printing company R.R. Donnelley & Sons Co. is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.","news_type":1,"symbols_score_info":{"EXPR":0.9,"NAKD":0.9,"BB":0.9,"KOSS":0.9,"BBBY":0.9,"GME":0.9,"AMC":0.9,"RRD":0.9}},"isVote":1,"tweetType":1,"viewCount":1969,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843581898,"gmtCreate":1635841643487,"gmtModify":1635841646978,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Go go go!!!&nbsp;","listText":"Go go go!!!&nbsp;","text":"Go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843581898","repostId":"1146954113","repostType":2,"repost":{"id":"1146954113","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635841327,"share":"https://www.laohu8.com/m/news/1146954113?lang=zh_CN&edition=full","pubTime":"2021-11-02 16:22","market":"us","language":"en","title":"Novavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1146954113","media":"Tiger Newspress","summary":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as","content":"<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p><p><blockquote>随着Novavax COVID-19疫苗获得首次授权，Novavax股价继昨天上涨近16%后，周二盘前交易中又上涨4.4%；预计几周内会有更多。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p><p><blockquote>Novavax Inc.首席执行官告诉路透社，预计印度、菲律宾和其他地方的监管机构将在“几周内”就其COVID-19疫苗做出决定，此前该疫苗周一获得了印度尼西亚的首次紧急使用授权（EUA）。</blockquote></p><p> The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p><p><blockquote>该公司还表示，已向加拿大和欧洲药品管理局提交了紧急使用该疫苗的申请。</blockquote></p><p> For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p><p><blockquote>对于印度尼西亚，该疫苗将由世界上最大的疫苗制造商印度血清研究所（SII）生产，并以印度公司的品牌Covovax销售。Novavax表示，预计即将开始向印度尼西亚发货。</blockquote></p><p> The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p><p><blockquote>世界卫生组织(WHO)也在审查Novavax的监管文件，这家美国制药商预计审查将在未来几周内得到解决，首席执行官斯坦利·埃尔克(Stanley Erck)周一在接受路透社电话采访时表示。</blockquote></p><p> A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p><p><blockquote>世卫组织的批准将为Novavax开始向向低收入国家提供疫苗的COVAX计划运送疫苗奠定基础。Novavax和SII共同承诺向世卫组织共同领导的COVAX提供超过11亿剂疫苗。</blockquote></p><p> “I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p><p><blockquote>“我认为我们今年会向COVAX提供一些剂量，”埃尔克说。“但我认为（Novavax）将在2022年第一季度真正开始能够向COVAX运送大量货物”。</blockquote></p><p> Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p><p><blockquote>Erck表示，Novavax已经解决了所有制造挑战，预计监管机构不会对其生产流程产生任何进一步的担忧。</blockquote></p><p> He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p><p><blockquote>他表示，Novavax“正在与美国FDA进行对话……我们预计将在未来几周内提交完整的申请。”</blockquote></p><p> Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p><p><blockquote>Novavax推迟了申请美国批准的时间，Politico上个月报道称，该公司面临生产和质量问题。</blockquote></p><p> SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p><p><blockquote>SII被授权生产Novavax疫苗，这家美国公司表示，将在未来几周内为其他设施申请监管授权，例如其在捷克共和国的工厂。</blockquote></p><p> Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p><p><blockquote>据政府称，印度尼西亚今年预计将收到2000万剂基于蛋白质的疫苗。</blockquote></p><p> Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p><p><blockquote>印度尼西亚国家药品和食品管制局局长彭妮·卢基托没有立即回应路透社的置评请求。</blockquote></p><p> Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p><p><blockquote>Novavax迄今已在多个国家申请EUA，包括英国、澳大利亚、印度和菲律宾。</blockquote></p><p> “It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p><p><blockquote>埃尔克表示，“他们需要几周而不是几个月的时间来审查”Novavax的监管文件，并可能批准使用该疫苗。</blockquote></p><p> The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p><p><blockquote>该公司与日本合作伙伴武田制药公司周五表示，正准备寻求监管部门批准明年初在日本推出。</blockquote></p><p> The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p><p><blockquote>在美国的一项大型后期试验中，Novavax疫苗的有效性超过90%，包括针对各种令人担忧的冠状病毒变种。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-02 16:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p><p><blockquote>随着Novavax COVID-19疫苗获得首次授权，Novavax股价继昨天上涨近16%后，周二盘前交易中又上涨4.4%；预计几周内会有更多。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p><p><blockquote>Novavax Inc.首席执行官告诉路透社，预计印度、菲律宾和其他地方的监管机构将在“几周内”就其COVID-19疫苗做出决定，此前该疫苗周一获得了印度尼西亚的首次紧急使用授权（EUA）。</blockquote></p><p> The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p><p><blockquote>该公司还表示，已向加拿大和欧洲药品管理局提交了紧急使用该疫苗的申请。</blockquote></p><p> For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p><p><blockquote>对于印度尼西亚，该疫苗将由世界上最大的疫苗制造商印度血清研究所（SII）生产，并以印度公司的品牌Covovax销售。Novavax表示，预计即将开始向印度尼西亚发货。</blockquote></p><p> The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p><p><blockquote>世界卫生组织(WHO)也在审查Novavax的监管文件，这家美国制药商预计审查将在未来几周内得到解决，首席执行官斯坦利·埃尔克(Stanley Erck)周一在接受路透社电话采访时表示。</blockquote></p><p> A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p><p><blockquote>世卫组织的批准将为Novavax开始向向低收入国家提供疫苗的COVAX计划运送疫苗奠定基础。Novavax和SII共同承诺向世卫组织共同领导的COVAX提供超过11亿剂疫苗。</blockquote></p><p> “I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p><p><blockquote>“我认为我们今年会向COVAX提供一些剂量，”埃尔克说。“但我认为（Novavax）将在2022年第一季度真正开始能够向COVAX运送大量货物”。</blockquote></p><p> Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p><p><blockquote>Erck表示，Novavax已经解决了所有制造挑战，预计监管机构不会对其生产流程产生任何进一步的担忧。</blockquote></p><p> He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p><p><blockquote>他表示，Novavax“正在与美国FDA进行对话……我们预计将在未来几周内提交完整的申请。”</blockquote></p><p> Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p><p><blockquote>Novavax推迟了申请美国批准的时间，Politico上个月报道称，该公司面临生产和质量问题。</blockquote></p><p> SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p><p><blockquote>SII被授权生产Novavax疫苗，这家美国公司表示，将在未来几周内为其他设施申请监管授权，例如其在捷克共和国的工厂。</blockquote></p><p> Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p><p><blockquote>据政府称，印度尼西亚今年预计将收到2000万剂基于蛋白质的疫苗。</blockquote></p><p> Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p><p><blockquote>印度尼西亚国家药品和食品管制局局长彭妮·卢基托没有立即回应路透社的置评请求。</blockquote></p><p> Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p><p><blockquote>Novavax迄今已在多个国家申请EUA，包括英国、澳大利亚、印度和菲律宾。</blockquote></p><p> “It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p><p><blockquote>埃尔克表示，“他们需要几周而不是几个月的时间来审查”Novavax的监管文件，并可能批准使用该疫苗。</blockquote></p><p> The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p><p><blockquote>该公司与日本合作伙伴武田制药公司周五表示，正准备寻求监管部门批准明年初在日本推出。</blockquote></p><p> The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p><p><blockquote>在美国的一项大型后期试验中，Novavax疫苗的有效性超过90%，包括针对各种令人担忧的冠状病毒变种。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146954113","content_text":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as Novavax COVID-19 vaccine got first authorization; expected more within weeks.\n\nNovavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.\nThe company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.\nFor Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.\nThe World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.\nA green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.\n“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.\nErck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.\nHe said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”\nNovavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.\nSII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.\nIndonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.\nPenny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.\nNovavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.\n“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.\nThe company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.\nThe Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851838102,"gmtCreate":1634890474595,"gmtModify":1634890474595,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","text":"$AMD(AMD)$ up up up!!!","images":[{"img":"https://static.tigerbbs.com/2da1478496dda3d23161f71934bb6c2b","width":"1080","height":"2375"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851838102","isVote":1,"tweetType":1,"viewCount":2301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859499264,"gmtCreate":1634718770094,"gmtModify":1634721067878,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Gg&nbsp;overpromise again","listText":"Gg&nbsp;overpromise again","text":"Gg overpromise again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859499264","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=zh_CN&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-20 16:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850281587,"gmtCreate":1634602242348,"gmtModify":1634602242420,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Very good","listText":"Very good","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850281587","repostId":"1114416896","repostType":4,"isVote":1,"tweetType":1,"viewCount":2414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829410404,"gmtCreate":1633532533184,"gmtModify":1633532533259,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"But why stock price still drop??&nbsp;","listText":"But why stock price still drop??&nbsp;","text":"But why stock price still drop??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829410404","repostId":"1169679917","repostType":2,"isVote":1,"tweetType":1,"viewCount":2190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829404697,"gmtCreate":1633530962458,"gmtModify":1633530962530,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"why sell???","listText":"why sell???","text":"why sell???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829404697","repostId":"1126696993","repostType":2,"isVote":1,"tweetType":1,"viewCount":2329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":839362705,"gmtCreate":1629122847907,"gmtModify":1633687233567,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"loving the reds","listText":"loving the reds","text":"loving the reds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839362705","repostId":"1133200546","repostType":4,"isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166466282,"gmtCreate":1624023123946,"gmtModify":1634023985172,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166466282","repostId":"1147049745","repostType":4,"repost":{"id":"1147049745","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624018214,"share":"https://www.laohu8.com/m/news/1147049745?lang=zh_CN&edition=full","pubTime":"2021-06-18 20:10","market":"us","language":"en","title":"Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的营收</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147049745","media":"Tiger Newspress","summary":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to","content":"<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p><p><blockquote>美国股指期货周五下跌，因为在美联储最新政策更新后，标普500和道琼斯工业平均指数预计将出现本周下跌。</blockquote></p><p> At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p><p><blockquote>截至美国东部时间上午8:05，道指E-minis下跌153点，跌幅0.45%，标普500 E-minis下跌14.75点，跌幅0.35%，纳斯达克100 E-minis下跌18.5点，跌幅0.13%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:05</span></p></blockquote></p><p> The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p><p><blockquote>蓝筹股道琼斯指数本周迄今已下跌1.9%，创下1月份以来最糟糕的一周。标普500下跌0.6%。但纳斯达克本周上涨了0.65%。</blockquote></p><p> The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p><p><blockquote>股市下跌之际，所谓的国债收益率曲线急剧变平，2年期国债等短期国债收益率上升，而基准10年期国债等长期国债收益率下降。长期债券的回落反映了对经济增长的不太乐观，而短期收益率的跃升则显示了美联储加息的预期。</blockquote></p><p> The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p><p><blockquote>央行周三的鹰派转向导致股市和债市波动。美联储官员在2023年的预测中增加了两次加息，并提高了今年的通胀预测，而美联储主席鲍威尔表示，官员们已经讨论了缩减债券购买，并将在某个时候开始放缓资产购买。</blockquote></p><p> Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p><p><blockquote>周五也恰逢季度“四重巫术”，指数和股票的期权和期货到期。许多人预计，鉴于这一事件，交易将更加波动。</blockquote></p><p> <b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p><p><blockquote><b>Adobe(ADBE)</b>-Adobe报告季度利润为每股3.03美元，比预期高出每股21美分。该软件公司的收入也超出了华尔街的预期，Adobe给出了强于预期的本季度指引。其股价在盘前交易中上涨3.1%。</blockquote></p><p> <b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p><p><blockquote><b>史密斯威森(SWBI)</b>-Smith&amp;Wesson报告其最新季度的利润和销售额好于预期，该枪支制造商的销售额与去年同期相比飙升了67%。该公司指出，其出货量增长了70%，而行业整体增长率为42%。股价在盘前交易中上涨4.7%。</blockquote></p><p> <b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p><p><blockquote><b>Orphazyme(ORPH)</b>-在美国食品和药物管理局拒绝其对尼曼-皮克病C型遗传疾病的实验性治疗后，Orphazyme在盘前暴跌52.6%。这家总部位于丹麦的生物技术公司最近几天股价波动较大社交媒体关注度在周三飙升超过61%后，周四下跌10.2%。</blockquote></p><p> <b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p><p><blockquote><b>达美航空(DAL)</b>-Wolfe Research将评级从“跑输大盘”上调至“跑赢大盘”后，该股盘前上涨1.1%。沃尔夫表示，预计今年夏天晚些时候商务旅行将受益于被压抑的需求，尽管它认为不会恢复到新冠疫情爆发前的水平。</blockquote></p><p> <b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p><p><blockquote><b>曼联(MANU)</b>-曼联今年前三个月损失了3020万美元，主要是由于冠状病毒大流行导致球迷缺席比赛。球队2020-21赛季的所有比赛都是在没有观众的情况下进行的。</blockquote></p><p> <b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p><p><blockquote><b>安赛乐米塔尔(MT)</b>-安赛乐米塔尔出售了钢铁生产商克利夫兰克利夫斯(CLF)剩余的3820万股股票。该矿业公司将利用所得款项为7.5亿美元的股票回购提供资金。阿塞洛-米塔尔(Arcelor-Mittal)盘前上涨1%，克利夫兰克利夫斯(Cleveland-Cliffs)上涨0.3%。</blockquote></p><p> <b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p><p><blockquote><b>嘉年华(CCL)</b>-该邮轮运营商披露了3月份的数据泄露事件，该事件可能暴露了其嘉年华、荷美和公主品牌客户的个人信息。它没有透露有多少人可能受到影响。</blockquote></p><p> <b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p><p><blockquote><b>福克斯公司(FOXA)</b>-福克斯将股票回购计划增加了20亿美元，总额达到40亿美元，帮助其股价在盘前上涨2.8%。</blockquote></p><p> <b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p><p><blockquote><b>朝圣者的骄傲(PPC)</b>–Pilgrim's Pride透过收购嘉里集团的肉类及膳食业务，扩展其熟食及品牌产品业务。这家家禽生产商将向这家总部位于爱尔兰的公司支付约9.47亿美元购买该设备。</blockquote></p><p> <b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p><p><blockquote><b>孩之宝(HAS)、美泰(MAT)</b>-《纽约邮报》的一篇报道警告即将到来的假期可能会出现玩具短缺，玩具制造商正在密切关注。该报称，由于缺乏可供出口的集装箱，数千件准备装运的玩具仍储存在中国。</blockquote></p><p> <b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p><p><blockquote><b>Biogen(BIIB)</b>–Piper Sandler将该制药商的股票从“中性”上调至“跑赢大盘”，该评级引用了许多因素，包括医生可能会开百健新批准的阿尔茨海默病药物Aduhelm。百健(Biogen)股价盘前上涨1.7%。</blockquote></p><p></p><p> <b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p><p><blockquote><b>花旗集团(C)</b>-该银行股价在过去连续11个交易日下跌后仍受到关注，在此期间下跌了14%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的营收</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday<blockquote>周五美国市场开盘前的营收</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-18 20:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>U.S. stock futures fell on Friday as the S&amp;P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.</p><p><blockquote>美国股指期货周五下跌，因为在美联储最新政策更新后，标普500和道琼斯工业平均指数预计将出现本周下跌。</blockquote></p><p> At 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&amp;P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.</p><p><blockquote>截至美国东部时间上午8:05，道指E-minis下跌153点，跌幅0.45%，标普500 E-minis下跌14.75点，跌幅0.35%，纳斯达克100 E-minis下跌18.5点，跌幅0.13%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/25234fe10c0fe8a9e73f2cec66447216\" tg-width=\"1003\" tg-height=\"316\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:05</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:05</span></p></blockquote></p><p> The blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&amp;P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.</p><p><blockquote>蓝筹股道琼斯指数本周迄今已下跌1.9%，创下1月份以来最糟糕的一周。标普500下跌0.6%。但纳斯达克本周上涨了0.65%。</blockquote></p><p> The decline in stocks came amid a drastic flattening of the so-called Treasury yield curve&nbsp;where the yields of shorter-duration Treasurys, like the&nbsp;2-year note, rose, while longer duration yields, such as the benchmark 10-year fell.&nbsp;The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.</p><p><blockquote>股市下跌之际，所谓的国债收益率曲线急剧变平，2年期国债等短期国债收益率上升，而基准10年期国债等长期国债收益率下降。长期债券的回落反映了对经济增长的不太乐观，而短期收益率的跃升则显示了美联储加息的预期。</blockquote></p><p> The central bank's hawkish pivot on Wednesday&nbsp;caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.</p><p><blockquote>央行周三的鹰派转向导致股市和债市波动。美联储官员在2023年的预测中增加了两次加息，并提高了今年的通胀预测，而美联储主席鲍威尔表示，官员们已经讨论了缩减债券购买，并将在某个时候开始放缓资产购买。</blockquote></p><p> Friday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.</p><p><blockquote>周五也恰逢季度“四重巫术”，指数和股票的期权和期货到期。许多人预计，鉴于这一事件，交易将更加波动。</blockquote></p><p> <b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b>Adobe(ADBE) </b>– Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.</p><p><blockquote><b>Adobe(ADBE)</b>-Adobe报告季度利润为每股3.03美元，比预期高出每股21美分。该软件公司的收入也超出了华尔街的预期，Adobe给出了强于预期的本季度指引。其股价在盘前交易中上涨3.1%。</blockquote></p><p> <b>Smith &amp; Wesson(SWBI) </b>– Smith &amp; Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.</p><p><blockquote><b>史密斯威森(SWBI)</b>-Smith&amp;Wesson报告其最新季度的利润和销售额好于预期，该枪支制造商的销售额与去年同期相比飙升了67%。该公司指出，其出货量增长了70%，而行业整体增长率为42%。股价在盘前交易中上涨4.7%。</blockquote></p><p> <b>Orphazyme(ORPH)</b> – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.</p><p><blockquote><b>Orphazyme(ORPH)</b>-在美国食品和药物管理局拒绝其对尼曼-皮克病C型遗传疾病的实验性治疗后，Orphazyme在盘前暴跌52.6%。这家总部位于丹麦的生物技术公司最近几天股价波动较大社交媒体关注度在周三飙升超过61%后，周四下跌10.2%。</blockquote></p><p> <b>Delta Air Lines(DAL)</b> – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.</p><p><blockquote><b>达美航空(DAL)</b>-Wolfe Research将评级从“跑输大盘”上调至“跑赢大盘”后，该股盘前上涨1.1%。沃尔夫表示，预计今年夏天晚些时候商务旅行将受益于被压抑的需求，尽管它认为不会恢复到新冠疫情爆发前的水平。</blockquote></p><p> <b>Manchester United(MANU) </b>– Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.</p><p><blockquote><b>曼联(MANU)</b>-曼联今年前三个月损失了3020万美元，主要是由于冠状病毒大流行导致球迷缺席比赛。球队2020-21赛季的所有比赛都是在没有观众的情况下进行的。</blockquote></p><p> <b>ArcelorMittal(MT) </b>– ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.</p><p><blockquote><b>安赛乐米塔尔(MT)</b>-安赛乐米塔尔出售了钢铁生产商克利夫兰克利夫斯(CLF)剩余的3820万股股票。该矿业公司将利用所得款项为7.5亿美元的股票回购提供资金。阿塞洛-米塔尔(Arcelor-Mittal)盘前上涨1%，克利夫兰克利夫斯(Cleveland-Cliffs)上涨0.3%。</blockquote></p><p> <b>Carnival(CCL) </b>– The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.</p><p><blockquote><b>嘉年华(CCL)</b>-该邮轮运营商披露了3月份的数据泄露事件，该事件可能暴露了其嘉年华、荷美和公主品牌客户的个人信息。它没有透露有多少人可能受到影响。</blockquote></p><p> <b>Fox Corp.(FOXA) </b>– Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.</p><p><blockquote><b>福克斯公司(FOXA)</b>-福克斯将股票回购计划增加了20亿美元，总额达到40亿美元，帮助其股价在盘前上涨2.8%。</blockquote></p><p> <b>Pilgrim's Pride(PPC) </b>– Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.</p><p><blockquote><b>朝圣者的骄傲(PPC)</b>–Pilgrim's Pride透过收购嘉里集团的肉类及膳食业务，扩展其熟食及品牌产品业务。这家家禽生产商将向这家总部位于爱尔兰的公司支付约9.47亿美元购买该设备。</blockquote></p><p> <b>Hasbro(HAS),Mattel(MAT) </b>– The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.</p><p><blockquote><b>孩之宝(HAS)、美泰(MAT)</b>-《纽约邮报》的一篇报道警告即将到来的假期可能会出现玩具短缺，玩具制造商正在密切关注。该报称，由于缺乏可供出口的集装箱，数千件准备装运的玩具仍储存在中国。</blockquote></p><p> <b>Biogen(BIIB)</b> – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.</p><p><blockquote><b>Biogen(BIIB)</b>–Piper Sandler将该制药商的股票从“中性”上调至“跑赢大盘”，该评级引用了许多因素，包括医生可能会开百健新批准的阿尔茨海默病药物Aduhelm。百健(Biogen)股价盘前上涨1.7%。</blockquote></p><p></p><p> <b>Citigroup(C) </b>– The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.</p><p><blockquote><b>花旗集团(C)</b>-该银行股价在过去连续11个交易日下跌后仍受到关注，在此期间下跌了14%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147049745","content_text":"U.S. stock futures fell on Friday as the S&P 500 and the Dow Jones Industrial Average are on pace to post a losing week after the Federal Reserve's latest policy update.\nAt 8:05 a.m. ET, Dow E-minis were down 153 points, or 0.45%, S&P 500 E-minis were down 14.75 points, or 0.35% and Nasdaq 100 E-minis fell 18.5 points, or 0.13%.\n*Source From Tiger Trade, EST 08:05\nThe blue-chip Dow has lost 1.9% week to date, on pace for its worst week since January. The S&P 500 has fallen 0.6%. But the Nasdaq has gained 0.65% on the week.\nThe decline in stocks came amid a drastic flattening of the so-called Treasury yield curve where the yields of shorter-duration Treasurys, like the 2-year note, rose, while longer duration yields, such as the benchmark 10-year fell. The retreat in long-dated bonds reflects less optimism toward the economic growth, while the jump in short-end yields shows the expectations of the Fed raising rates.\nThe central bank's hawkish pivot on Wednesday caused volatile stock and bond market moves. Fed officials added two rate hikes to their 2023 forecast and increased their inflation projection for the year, while Fed Chairman Jerome Powell said officials have discussed tapering bond buying and would at some point begin slowing the asset purchases.\nFriday also coincides with the quarterly \"quadruple witching\" where options and futures on indexes and equities expire. Many expect trading to be more volatile in light of this event.\nStocks making the biggest moves in the premarket:\nAdobe(ADBE) – Adobe reported quarterly profit of $3.03 per share, 21 cents a share above estimates. The software company's revenue also topped Wall Street forecasts and Adobe gave stronger-than-expected current-quarter guidance. Its shares rose 3.1% in premarket trading.\nSmith & Wesson(SWBI) – Smith & Wesson reported better-than-expected profit and sales for its latest quarter, as the gun maker's sales surged 67% compared to the same quarter a year earlier. The company notes that its shipments jumped 70% compared to overall industry growth of 42%. Shares rallied 4.7% in premarket trading.\nOrphazyme(ORPH) – Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its experimental treatment for a genetic disorder known as Niemann-Pick disease type C. The Denmark-based biotech company had seen volatile trading in its shares in recent days after it picked up social media attention, falling 10.2% Thursday after a more than 61% surge Wednesday.\nDelta Air Lines(DAL) – The stock added 1.1% in the premarket following a double upgrade at Wolfe Research to \"outperform\" from \"underperform.\" Wolfe said it sees business travel benefiting from pent-up demand later this summer, although it doesn't think it will return to pre-Covid levels.\nManchester United(MANU) – Manchester United lost $30.2 million for the first three months of this year, due largely to the absence of fans at its games because of the coronavirus pandemic. All of the team's 2020-21 season games were played without spectators.\nArcelorMittal(MT) – ArcelorMittal sold its remaining 38.2 million shares of steel producerCleveland-Cliffs(CLF). The mining company will use the proceeds to fund a $750 million share buyback. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%.\nCarnival(CCL) – The cruise line operator disclosed a March data breach that may have exposed personal information of customers of its Carnival, Holland America and Princess brands. It did not disclose how many may have been affected.\nFox Corp.(FOXA) – Fox increased its stock repurchase program by $2 billion to a total of $4 billion, helping to send its shares higher by 2.8% in the premarket.\nPilgrim's Pride(PPC) – Pilgrim's Pride expanded its prepared foods and branded products business by purchasing Kerry Group's Meats and Meals business. The poultry producer will pay the Ireland-based company about $947 million for that unit.\nHasbro(HAS),Mattel(MAT) – The toymakers are on watch following a New York Post report warning of a potential toy shortage this coming holiday season. The paper said thousands of toys ready for shipment remain stockpiled in China due to the lack of shipping containers available for export.\nBiogen(BIIB) – The drugmaker's stock was upgraded to \"overweight\" from \"neutral\" at Piper Sandler, which cites a number of factors including the likelihood that doctors will prescribe Biogen's newly approved Alzheimer's drug Aduhelm. Biogen shares rose 1.7% in the premarket.\nCitigroup(C) – The bank's stock remains on watch after declining for the past 11 consecutive trading days, losing 14% over that time.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168915787,"gmtCreate":1623946605949,"gmtModify":1631889070690,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Team red!!","listText":"Team red!!","text":"Team red!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168915787","repostId":"2144374429","repostType":4,"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169438674,"gmtCreate":1623846707598,"gmtModify":1634027192711,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Sick. Need more dips","listText":"Sick. Need more dips","text":"Sick. Need more dips","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169438674","repostId":"1185341836","repostType":4,"repost":{"id":"1185341836","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623845207,"share":"https://www.laohu8.com/m/news/1185341836?lang=zh_CN&edition=full","pubTime":"2021-06-16 20:06","market":"hk","language":"en","title":"Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1185341836","media":"Tiger Newspress","summary":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on mone","content":"<p>U.S. stock index futures were mostly flat on Wednesday ahead of the&nbsp;Federal Reserve's update&nbsp;on monetary policy.</p><p><blockquote>在美联储公布货币政策更新之前，美国股指期货周三大多持平。</blockquote></p><p> Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&amp;P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p><p><blockquote>与道琼斯工业平均指数挂钩的期货合约仅下跌46点。标普500期货基本持平，纳斯达克100期货上涨0.1%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:10</span></p></blockquote></p><p> The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p><p><blockquote>美联储此前曾试图缓解人们对通胀上升将促使其收紧超宽松货币政策的担忧，但周二显示生产者价格上涨的数据再次引发了人们对美联储可能在本周会议上开始讨论关闭水龙头的预期。</blockquote></p><p> The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p><p><blockquote>央行最新的政策声明预计将于下午2点发布，其中包含新的经济预测。美国东部时间（格林威治标准时间1800）。</blockquote></p><p> <b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p><p><blockquote><b>甲骨文(ORCL)</b>-甲骨文最近一个季度的每股收益为1.54美元，超出了每股1.31美元的普遍预期。这家商业软件公司的收入也超出了预期。然而，由于增加了对云计算业务的投资，该公司预计本季度利润将低于市场普遍预期。其股价在盘前交易中下跌4.7%。</blockquote></p><p> <b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p><p><blockquote><b>机器人(RBLX)</b>-Roblox公布5月份日活跃用户为4300万，同比增长28%，但低于4月份的4330万，盘前下跌7.7%。视频游戏平台用户的支出较去年同期略有下降。</blockquote></p><p> <b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p><p><blockquote><b>亲族生物科学公司(KIN)</b>–宠物治疗公司同意被Elanco Animal Health(ELAN)以每股9.25美元（即4.4亿美元）收购。Kindred周二收于6.34美元，其股价盘前飙升44.6%。</blockquote></p><p> <b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p><p><blockquote><b>La-Z-Boy(LZB)</b>-La-Z-Boy报告季度收益为每股87美分，而市场普遍预期为每股74美分。这家以躺椅闻名的公司也公布了好于预期的收入。La-Z-Boy表示，该公司正受到供应链问题和原材料价格大幅上涨的影响。其股价盘前下跌2.3%。</blockquote></p><p> <b>H&amp;R Block(HRB)</b> – H&amp;R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&amp;R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&amp;R Block shares slid 1.1% in premarket action.</p><p><blockquote><b>H&amp;R区块(HRB)</b>–H&amp;R Block最近一个季度的利润和收入均超出了华尔街的预期，该税务准备公司还将季度股息提高了4%，至每股27美分。此外，H&amp;R Block将其财年结束时间从4月30日推迟到6月30日，以更好地捕捉报税活动。H&amp;R Block股价在盘前下跌1.1%。</blockquote></p><p> <b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p><p><blockquote><b>EBay（EBay）</b>-据当地媒体报道，这家在线市场运营商将以约36亿美元的价格将其韩国部门出售给零售商Shinsegae的E-Mart部门和网站运营商Naver。易买得承认进行了谈判，但表示尚未敲定任何交易。</blockquote></p><p> <b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p><p><blockquote><b>通用汽车(GM)</b>-据报道，通用汽车计划到2025年将全球电动和自动驾驶汽车支出比最新预测增加30%，达到350亿美元。了解该计划的人士告诉路透社，这笔支出将包括另外两家美国电池厂。</blockquote></p><p> <b>Johnson &amp; Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&amp;J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p><p><blockquote><b>强生公司(JNJ)</b>-美国食品和药物管理局批准了另外1500万剂强生Covid-19疫苗，该疫苗是在Emergent BioSolutions(EBS)运营的巴尔的摩工厂生产的。这使得批准的总剂量达到2500万剂。早些时候，FDA拒绝了该工厂生产的6000万剂疫苗，称Emergent没有采取适当的预防措施来防止与另一条生产阿斯利康(AZN)新冠疫苗的生产线交叉污染。</blockquote></p><p> <b>Southwest Airlines(LUV) </b>– Southwest&nbsp;suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p><p><blockquote><b>西南航空(LUV)</b>–周二，西南航空遭遇24小时内第二次计算机故障，系统中断导致约500个航班取消，许多航班延误。</blockquote></p><p> <b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p><p><blockquote><b>碟形网络(DISH)</b>–Pivotal Research将这家卫星电视公司从“持有”上调至“买入”，该公司指出了Dish 5G无线网络的潜力。Dish盘前上涨1.7%。</blockquote></p><p> <b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p><p><blockquote><b>阿波罗全球(APO)</b>–Apollo以45亿美元的价格将教科书和教育技术公司McGraw Hill出售给私募股权公司Platinum Equity。</blockquote></p><p> <b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p><p><blockquote><b>再生元(REGN)</b>-根据英国新发表的一项研究，该制药商的sCovid-19抗体鸡尾酒减少了无法产生自身抗体反应的患者的死亡。</blockquote></p><p> <b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p><p><blockquote><b>索菲科技(SOFI)</b>-该金融服务平台在Rosenblatt Securities的新报道中被评为“买入”，指出SoFi相对于传统银行具有“强大”的成本优势。SoFi股价盘前上涨2.1%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday<blockquote>周三美国市场开盘前的顶线</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-16 20:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>U.S. stock index futures were mostly flat on Wednesday ahead of the&nbsp;Federal Reserve's update&nbsp;on monetary policy.</p><p><blockquote>在美联储公布货币政策更新之前，美国股指期货周三大多持平。</blockquote></p><p> Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&amp;P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p><p><blockquote>与道琼斯工业平均指数挂钩的期货合约仅下跌46点。标普500期货基本持平，纳斯达克100期货上涨0.1%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p><p><blockquote><p class=\"t-img-caption\"><span>*来源自Tiger Trade，美国东部时间08:10</span></p></blockquote></p><p> The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p><p><blockquote>美联储此前曾试图缓解人们对通胀上升将促使其收紧超宽松货币政策的担忧，但周二显示生产者价格上涨的数据再次引发了人们对美联储可能在本周会议上开始讨论关闭水龙头的预期。</blockquote></p><p> The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p><p><blockquote>央行最新的政策声明预计将于下午2点发布，其中包含新的经济预测。美国东部时间（格林威治标准时间1800）。</blockquote></p><p> <b>Stocks making the biggest moves in the premarket:</b></p><p><blockquote><b>盘前涨幅最大的股票：</b></blockquote></p><p> <b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p><p><blockquote><b>甲骨文(ORCL)</b>-甲骨文最近一个季度的每股收益为1.54美元，超出了每股1.31美元的普遍预期。这家商业软件公司的收入也超出了预期。然而，由于增加了对云计算业务的投资，该公司预计本季度利润将低于市场普遍预期。其股价在盘前交易中下跌4.7%。</blockquote></p><p> <b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p><p><blockquote><b>机器人(RBLX)</b>-Roblox公布5月份日活跃用户为4300万，同比增长28%，但低于4月份的4330万，盘前下跌7.7%。视频游戏平台用户的支出较去年同期略有下降。</blockquote></p><p> <b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p><p><blockquote><b>亲族生物科学公司(KIN)</b>–宠物治疗公司同意被Elanco Animal Health(ELAN)以每股9.25美元（即4.4亿美元）收购。Kindred周二收于6.34美元，其股价盘前飙升44.6%。</blockquote></p><p> <b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p><p><blockquote><b>La-Z-Boy(LZB)</b>-La-Z-Boy报告季度收益为每股87美分，而市场普遍预期为每股74美分。这家以躺椅闻名的公司也公布了好于预期的收入。La-Z-Boy表示，该公司正受到供应链问题和原材料价格大幅上涨的影响。其股价盘前下跌2.3%。</blockquote></p><p> <b>H&amp;R Block(HRB)</b> – H&amp;R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&amp;R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&amp;R Block shares slid 1.1% in premarket action.</p><p><blockquote><b>H&amp;R区块(HRB)</b>–H&amp;R Block最近一个季度的利润和收入均超出了华尔街的预期，该税务准备公司还将季度股息提高了4%，至每股27美分。此外，H&amp;R Block将其财年结束时间从4月30日推迟到6月30日，以更好地捕捉报税活动。H&amp;R Block股价在盘前下跌1.1%。</blockquote></p><p> <b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p><p><blockquote><b>EBay（EBay）</b>-据当地媒体报道，这家在线市场运营商将以约36亿美元的价格将其韩国部门出售给零售商Shinsegae的E-Mart部门和网站运营商Naver。易买得承认进行了谈判，但表示尚未敲定任何交易。</blockquote></p><p> <b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p><p><blockquote><b>通用汽车(GM)</b>-据报道，通用汽车计划到2025年将全球电动和自动驾驶汽车支出比最新预测增加30%，达到350亿美元。了解该计划的人士告诉路透社，这笔支出将包括另外两家美国电池厂。</blockquote></p><p> <b>Johnson &amp; Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&amp;J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p><p><blockquote><b>强生公司(JNJ)</b>-美国食品和药物管理局批准了另外1500万剂强生Covid-19疫苗，该疫苗是在Emergent BioSolutions(EBS)运营的巴尔的摩工厂生产的。这使得批准的总剂量达到2500万剂。早些时候，FDA拒绝了该工厂生产的6000万剂疫苗，称Emergent没有采取适当的预防措施来防止与另一条生产阿斯利康(AZN)新冠疫苗的生产线交叉污染。</blockquote></p><p> <b>Southwest Airlines(LUV) </b>– Southwest&nbsp;suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p><p><blockquote><b>西南航空(LUV)</b>–周二，西南航空遭遇24小时内第二次计算机故障，系统中断导致约500个航班取消，许多航班延误。</blockquote></p><p> <b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p><p><blockquote><b>碟形网络(DISH)</b>–Pivotal Research将这家卫星电视公司从“持有”上调至“买入”，该公司指出了Dish 5G无线网络的潜力。Dish盘前上涨1.7%。</blockquote></p><p> <b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p><p><blockquote><b>阿波罗全球(APO)</b>–Apollo以45亿美元的价格将教科书和教育技术公司McGraw Hill出售给私募股权公司Platinum Equity。</blockquote></p><p> <b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p><p><blockquote><b>再生元(REGN)</b>-根据英国新发表的一项研究，该制药商的sCovid-19抗体鸡尾酒减少了无法产生自身抗体反应的患者的死亡。</blockquote></p><p> <b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p><p><blockquote><b>索菲科技(SOFI)</b>-该金融服务平台在Rosenblatt Securities的新报道中被评为“买入”，指出SoFi相对于传统银行具有“强大”的成本优势。SoFi股价盘前上涨2.1%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文",".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185341836","content_text":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on monetary policy.\nFutures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.\n*Source From Tiger Trade, EST 08:10\nThe Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.\nThe central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).\nStocks making the biggest moves in the premarket:\nOracle(ORCL) – Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.\nRoblox(RBLX) – Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.\nKindred Biosciences(KIN) – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.\nLa-Z-Boy(LZB) – La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.\nH&R Block(HRB) – H&R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&R Block shares slid 1.1% in premarket action.\nEBay(EBAY) – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.\nGeneral Motors(GM) – GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.\nJohnson & Johnson(JNJ) – The Food and Drug Administration cleared 15 million more doses of J&J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.\nSouthwest Airlines(LUV) – Southwest suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.\nDish Network(DISH) – The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.\nApollo Global(APO) – Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.\nRegeneron(REGN) – The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.\nSoFi Technologies(SOFI) – The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.","news_type":1,"symbols_score_info":{"ORCL":0.9,"KIN":0.9,".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169025031,"gmtCreate":1623809809123,"gmtModify":1634027774566,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169025031","repostId":"1144333499","repostType":4,"isVote":1,"tweetType":1,"viewCount":443,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187640213,"gmtCreate":1623753304332,"gmtModify":1634029017457,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187640213","repostId":"2143735244","repostType":4,"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187656548,"gmtCreate":1623753177184,"gmtModify":1634029021993,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Good to dip your toes into a little bit of crypto.&nbsp;","listText":"Good to dip your toes into a little bit of crypto.&nbsp;","text":"Good to dip your toes into a little bit of crypto.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187656548","repostId":"2143735752","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":871185699,"gmtCreate":1637037132655,"gmtModify":1637037302349,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Pls drop so that i can buy more","listText":"Pls drop so that i can buy more","text":"Pls drop so that i can buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/871185699","repostId":"1160740007","repostType":4,"isVote":1,"tweetType":1,"viewCount":2988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843581898,"gmtCreate":1635841643487,"gmtModify":1635841646978,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Go go go!!!&nbsp;","listText":"Go go go!!!&nbsp;","text":"Go go go!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843581898","repostId":"1146954113","repostType":2,"repost":{"id":"1146954113","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635841327,"share":"https://www.laohu8.com/m/news/1146954113?lang=zh_CN&edition=full","pubTime":"2021-11-02 16:22","market":"us","language":"en","title":"Novavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1146954113","media":"Tiger Newspress","summary":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as","content":"<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p><p><blockquote>随着Novavax COVID-19疫苗获得首次授权，Novavax股价继昨天上涨近16%后，周二盘前交易中又上涨4.4%；预计几周内会有更多。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p><p><blockquote>Novavax Inc.首席执行官告诉路透社，预计印度、菲律宾和其他地方的监管机构将在“几周内”就其COVID-19疫苗做出决定，此前该疫苗周一获得了印度尼西亚的首次紧急使用授权（EUA）。</blockquote></p><p> The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p><p><blockquote>该公司还表示，已向加拿大和欧洲药品管理局提交了紧急使用该疫苗的申请。</blockquote></p><p> For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p><p><blockquote>对于印度尼西亚，该疫苗将由世界上最大的疫苗制造商印度血清研究所（SII）生产，并以印度公司的品牌Covovax销售。Novavax表示，预计即将开始向印度尼西亚发货。</blockquote></p><p> The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p><p><blockquote>世界卫生组织(WHO)也在审查Novavax的监管文件，这家美国制药商预计审查将在未来几周内得到解决，首席执行官斯坦利·埃尔克(Stanley Erck)周一在接受路透社电话采访时表示。</blockquote></p><p> A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p><p><blockquote>世卫组织的批准将为Novavax开始向向低收入国家提供疫苗的COVAX计划运送疫苗奠定基础。Novavax和SII共同承诺向世卫组织共同领导的COVAX提供超过11亿剂疫苗。</blockquote></p><p> “I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p><p><blockquote>“我认为我们今年会向COVAX提供一些剂量，”埃尔克说。“但我认为（Novavax）将在2022年第一季度真正开始能够向COVAX运送大量货物”。</blockquote></p><p> Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p><p><blockquote>Erck表示，Novavax已经解决了所有制造挑战，预计监管机构不会对其生产流程产生任何进一步的担忧。</blockquote></p><p> He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p><p><blockquote>他表示，Novavax“正在与美国FDA进行对话……我们预计将在未来几周内提交完整的申请。”</blockquote></p><p> Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p><p><blockquote>Novavax推迟了申请美国批准的时间，Politico上个月报道称，该公司面临生产和质量问题。</blockquote></p><p> SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p><p><blockquote>SII被授权生产Novavax疫苗，这家美国公司表示，将在未来几周内为其他设施申请监管授权，例如其在捷克共和国的工厂。</blockquote></p><p> Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p><p><blockquote>据政府称，印度尼西亚今年预计将收到2000万剂基于蛋白质的疫苗。</blockquote></p><p> Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p><p><blockquote>印度尼西亚国家药品和食品管制局局长彭妮·卢基托没有立即回应路透社的置评请求。</blockquote></p><p> Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p><p><blockquote>Novavax迄今已在多个国家申请EUA，包括英国、澳大利亚、印度和菲律宾。</blockquote></p><p> “It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p><p><blockquote>埃尔克表示，“他们需要几周而不是几个月的时间来审查”Novavax的监管文件，并可能批准使用该疫苗。</blockquote></p><p> The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p><p><blockquote>该公司与日本合作伙伴武田制药公司周五表示，正准备寻求监管部门批准明年初在日本推出。</blockquote></p><p> The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p><p><blockquote>在美国的一项大型后期试验中，Novavax疫苗的有效性超过90%，包括针对各种令人担忧的冠状病毒变种。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares jumped another 4.4% in premarket trading<blockquote>Novavax股价在盘前交易中又上涨4.4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-02 16:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares jumped another 4.4% in premarket trading&nbsp;Tuesday&nbsp;after rising nearly 16% yesterday&nbsp;as&nbsp;Novavax COVID-19 vaccine got first authorization; expected more within weeks.</p><p><blockquote>随着Novavax COVID-19疫苗获得首次授权，Novavax股价继昨天上涨近16%后，周二盘前交易中又上涨4.4%；预计几周内会有更多。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/93777ff8ed669db1e3ea1516ae6b0f1f\" tg-width=\"849\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.</p><p><blockquote>Novavax Inc.首席执行官告诉路透社，预计印度、菲律宾和其他地方的监管机构将在“几周内”就其COVID-19疫苗做出决定，此前该疫苗周一获得了印度尼西亚的首次紧急使用授权（EUA）。</blockquote></p><p> The company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.</p><p><blockquote>该公司还表示，已向加拿大和欧洲药品管理局提交了紧急使用该疫苗的申请。</blockquote></p><p> For Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.</p><p><blockquote>对于印度尼西亚，该疫苗将由世界上最大的疫苗制造商印度血清研究所（SII）生产，并以印度公司的品牌Covovax销售。Novavax表示，预计即将开始向印度尼西亚发货。</blockquote></p><p> The World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.</p><p><blockquote>世界卫生组织(WHO)也在审查Novavax的监管文件，这家美国制药商预计审查将在未来几周内得到解决，首席执行官斯坦利·埃尔克(Stanley Erck)周一在接受路透社电话采访时表示。</blockquote></p><p> A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.</p><p><blockquote>世卫组织的批准将为Novavax开始向向低收入国家提供疫苗的COVAX计划运送疫苗奠定基础。Novavax和SII共同承诺向世卫组织共同领导的COVAX提供超过11亿剂疫苗。</blockquote></p><p> “I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.</p><p><blockquote>“我认为我们今年会向COVAX提供一些剂量，”埃尔克说。“但我认为（Novavax）将在2022年第一季度真正开始能够向COVAX运送大量货物”。</blockquote></p><p> Erck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.</p><p><blockquote>Erck表示，Novavax已经解决了所有制造挑战，预计监管机构不会对其生产流程产生任何进一步的担忧。</blockquote></p><p> He said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”</p><p><blockquote>他表示，Novavax“正在与美国FDA进行对话……我们预计将在未来几周内提交完整的申请。”</blockquote></p><p> Novavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.</p><p><blockquote>Novavax推迟了申请美国批准的时间，Politico上个月报道称，该公司面临生产和质量问题。</blockquote></p><p> SII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.</p><p><blockquote>SII被授权生产Novavax疫苗，这家美国公司表示，将在未来几周内为其他设施申请监管授权，例如其在捷克共和国的工厂。</blockquote></p><p> Indonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.</p><p><blockquote>据政府称，印度尼西亚今年预计将收到2000万剂基于蛋白质的疫苗。</blockquote></p><p> Penny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.</p><p><blockquote>印度尼西亚国家药品和食品管制局局长彭妮·卢基托没有立即回应路透社的置评请求。</blockquote></p><p> Novavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.</p><p><blockquote>Novavax迄今已在多个国家申请EUA，包括英国、澳大利亚、印度和菲律宾。</blockquote></p><p> “It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.</p><p><blockquote>埃尔克表示，“他们需要几周而不是几个月的时间来审查”Novavax的监管文件，并可能批准使用该疫苗。</blockquote></p><p> The company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.</p><p><blockquote>该公司与日本合作伙伴武田制药公司周五表示，正准备寻求监管部门批准明年初在日本推出。</blockquote></p><p> The Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.</p><p><blockquote>在美国的一项大型后期试验中，Novavax疫苗的有效性超过90%，包括针对各种令人担忧的冠状病毒变种。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146954113","content_text":"Novavax shares jumped another 4.4% in premarket trading Tuesday after rising nearly 16% yesterday as Novavax COVID-19 vaccine got first authorization; expected more within weeks.\n\nNovavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia.\nThe company also said it had filed an application for emergency use of the vaccine to Canada and the European Medicines Agency.\nFor Indonesia, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute in India (SII), and sold under the Indian company’s brand name, Covovax. Novavax said initial shipments into Indonesia are expected to begin imminently.\nThe World Health Organization (WHO) is also reviewing Novavax’s regulatory filing and the U.S. drugmaker expects that review to be resolved in the coming weeks, Chief Executive Stanley Erck told Reuters in a phone interview on Monday.\nA green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries. Novavax and SII have together committed to provide more than 1.1 billion doses to COVAX, which is co-led by the WHO.\n“I think we’ll get some doses to COVAX this year,” Erck said. “But I think (Novavax is) going to really start being able to ship large quantity to COVAX in the first quarter” of 2022.\nErck said Novavax has resolved all of its manufacturing challenges and does not expect regulators to have any further concerns about its production processes.\nHe said Novavax is “in dialogue with the U.S. FDA and ... we expect a full submission within the next several weeks.”\nNovavax had delayed filing for U.S. approval, and Politico reported last month that the company faced production and quality problems.\nSII is authorized to make the Novavax vaccine and the U.S. company said it will apply for regulatory authorization for other facilities, such as its plant in the Czech republic, in the coming weeks.\nIndonesia is slated to receive 20 million doses of the protein-based vaccine this year, according to the government.\nPenny Lukito, chief of the National Agency for Drug and Food Control of Indonesia, did not immediately respond to a Reuters request for comment.\nNovavax has so far applied for EUA in various countries, including the UK, Australia, India and the Philippines.\n“It will be weeks, not months, for them to review” Novavax’s regulatory submissions and potentially clear the shot for use, Erck said.\nThe company, along with Japanese partner Takeda Pharmaceutical Co, said on Friday it was preparing to seek regulatory approval for a rollout in Japan early next year.\nThe Novavax shot was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based trial.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841543109,"gmtCreate":1635928603322,"gmtModify":1635928603322,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"To the moon!!&nbsp;","listText":"To the moon!!&nbsp;","text":"To the moon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841543109","repostId":"1178338626","repostType":4,"repost":{"id":"1178338626","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635928227,"share":"https://www.laohu8.com/m/news/1178338626?lang=zh_CN&edition=full","pubTime":"2021-11-03 16:30","market":"us","language":"en","title":"Some meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1178338626","media":"Tiger Newspress","summary":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Bran","content":"<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p><p><blockquote>一些模因股票在盘前交易中飙升。Bed Bath&amp;Beyond, R.R.Donnelley&amp;Sons、Naked Brand、Koss、Express、AMC、游戏驿站和黑莓股价飙升4%至62%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p><p><blockquote><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">贝德柏士比昂公司</a>这家家居用品零售商宣布的消息可能引发了所谓的轧空，做空该股的对冲基金被迫回购股票以减少损失。</blockquote></p><p> Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p><p><blockquote>商业印刷公司。据知情人士透露，Donnelley&amp;Sons Co.即将达成协议，以略高于20亿美元（包括债务）的价格将自己出售给一家私募股权公司。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome meme stocks skyrocketed in premarket trading<blockquote>一些模因股票在盘前交易中飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-03 16:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some meme stocks skyrocketed in premarket trading.Bed Bath &amp; Beyond,R.R. Donnelley &amp; Sons,Naked Brand,Koss,Express,AMC,GameStop&nbsp;and&nbsp;BlackBerry&nbsp;soared between 4% and 62%.</p><p><blockquote>一些模因股票在盘前交易中飙升。Bed Bath&amp;Beyond, R.R.Donnelley&amp;Sons、Naked Brand、Koss、Express、AMC、游戏驿站和黑莓股价飙升4%至62%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b016995062645d8011221cff13a86966\" tg-width=\"404\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">Bed Bath &amp; Beyond</a>,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.</p><p><blockquote><a href=\"https://laohu8.com/NW/1113177921\" target=\"_blank\">贝德柏士比昂公司</a>这家家居用品零售商宣布的消息可能引发了所谓的轧空，做空该股的对冲基金被迫回购股票以减少损失。</blockquote></p><p> Commercial-printing company&nbsp;R.R. Donnelley &amp; Sons&nbsp;Co.&nbsp;is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.</p><p><blockquote>商业印刷公司。据知情人士透露，Donnelley&amp;Sons Co.即将达成协议，以略高于20亿美元（包括债务）的价格将自己出售给一家私募股权公司。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXPR":"Express, Inc.","AMC":"AMC院线","BBBY":"Bed Bath & Beyond, Inc.","BB":"黑莓","KOSS":"高斯电子","RRD":"当纳利","GME":"游戏驿站"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178338626","content_text":"Some meme stocks skyrocketed in premarket trading.Bed Bath & Beyond,R.R. Donnelley & Sons,Naked Brand,Koss,Express,AMC,GameStop and BlackBerry soared between 4% and 62%.\n\nBed Bath & Beyond,the home-goods retailer announced news that likely fueled a so-called short squeeze, where hedge funds that had bet against the stock were forced to buy back their shares to cut losses.\nCommercial-printing company R.R. Donnelley & Sons Co. is nearing a deal to sell itself to a private-equity firm for just over $2 billion including debt, according to people familiar with the matter.","news_type":1,"symbols_score_info":{"EXPR":0.9,"NAKD":0.9,"BB":0.9,"KOSS":0.9,"BBBY":0.9,"GME":0.9,"AMC":0.9,"RRD":0.9}},"isVote":1,"tweetType":1,"viewCount":1969,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859499264,"gmtCreate":1634718770094,"gmtModify":1634721067878,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Gg&nbsp;overpromise again","listText":"Gg&nbsp;overpromise again","text":"Gg overpromise again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859499264","repostId":"1174375951","repostType":2,"repost":{"id":"1174375951","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634717661,"share":"https://www.laohu8.com/m/news/1174375951?lang=zh_CN&edition=full","pubTime":"2021-10-20 16:14","market":"us","language":"en","title":"Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174375951","media":"Tiger Newspress","summary":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the pr","content":"<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax plunged over 20% in premarket trading<blockquote>Novavax盘前交易暴跌逾20%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-20 16:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Oct 20)&nbsp; <a href=\"https://laohu8.com/S/NVAX\">Novavax</a>&nbsp;may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.</p><p><blockquote>（10月20日）<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>可能因生产问题推迟10亿剂冠状病毒疫苗的交付。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f3995877f1c786d310a457ababf9ee9e\" tg-width=\"1043\" tg-height=\"564\" referrerpolicy=\"no-referrer\">The world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.</p><p><blockquote>这家全球疫苗分销商一直指望美国公司在2022年底前向中低收入国家提供超过20亿剂疫苗——这是结束Covid-19大流行的关键一步。</blockquote></p><p> But the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.</p><p><blockquote>但由名为COVAX的国际联盟发起的活动由于生产滞后而被大幅推迟，现在可能会短缺超过10亿剂，因为一家主要供应商在证明其能够生产疫苗方面面临重大障碍据三位直接了解该公司问题的人士透露，符合监管机构的质量标准。</blockquote></p><p> The delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.</p><p><blockquote>另外三名熟悉总部位于马里兰州的Novavax和拜登政府之间讨论的人士证实了这一延迟，这代表着在新的、更具传染性的变种出现后，为世界接种疫苗的努力遭遇重大挫折。</blockquote></p><p> The U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.</p><p><blockquote>美国政府在2020年向Novavax投资了16亿美元，这是当时向所有疫苗制造商投入的最多资金，希望它能为世界提供另一种安全有效的疫苗选择，以帮助预防Covid-19。但该公司一直遇到生产问题。据多位熟悉Novavax困难的人士透露，其用于测试疫苗纯度的方法未达到监管机构的标准，该公司也无法证明其能够生产出始终符合标准的疫苗。所有人都要求匿名，讨论敏感的公司对话。</blockquote></p><p> Although Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.</p><p><blockquote>据两位直接了解此事的人士透露，尽管Novavax最近在向美国证券交易委员会提交的季度文件中证实了其一些分析和测试问题，但该公司的问题比之前理解的更令人担忧。</blockquote></p><p> The Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.</p><p><blockquote>美国食品药品监督管理局根据2020年6月的冠状病毒疫苗指南，与每个制造商一起制定纯度水平，但普遍认为每个疫苗批次应至少达到90%。该公司一直在努力实现这一目标，<a href=\"https://laohu8.com/S/AONE.U\">一</a>的直接了解情况的人说。另一位熟悉该公司制造工艺的人士表示，Novavax最近的纯度水平徘徊在70%左右。低纯度水平会增加最终产品中存在污染物或不必要物质的机会，从而降低疫苗的有效性或增加患者对未知成分产生反应的机会。</blockquote></p><p> COVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.</p><p><blockquote>COVAX最近将2021年的目标从20亿剂下调至14.25亿剂，并已经估计，在为发展中国家接种疫苗的努力中，它面临着多达10亿剂的供应短缺。如果Novavax步履蹒跚，到2022年赤字可能会增加一倍，使数亿人对Covid-19没有免疫力，并延长疫情。</blockquote></p><p> “COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the <a href=\"https://laohu8.com/S/DRE\">Duke</a> Global Health Innovation Center.</p><p><blockquote>“COVAX继续面临充足供应的挑战……在这种背景下，Novavax的制造挑战和延误具有巨大的破坏性，”<a href=\"https://laohu8.com/S/DRE\">公爵</a>全球健康创新中心。</blockquote></p><p> The global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.</p><p><blockquote>全球联盟本月已经落后于数亿剂计划剂量，仅运送了10月份7亿剂目标中的3.71亿剂。它现在还面临着达不到已经下调的2021年目标的风险。</blockquote></p><p> Between Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.</p><p><blockquote>在Novavax和其他制造商的障碍之间，“COVAX不得不争先恐后地实时大幅修改其供应策略，”Udayakumar说。他补充说，因此，全球卫生组织强调提供更多捐款来满足眼前的需求。</blockquote></p><p> In a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.</p><p><blockquote>Novavax投资者关系和公司事务高级副总裁Silvia Taylor在一份声明中告诉POLITICO，该公司的分析测试方法已经过“验证”，但没有回答有关FDA是否已批准这些方法的问题。泰勒说，该公司仍计划在今年年底前提交紧急使用授权。</blockquote></p><p> “The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.</p><p><blockquote>泰勒说：“疫苗开发和监管提交过程非常复杂，通常需要数年时间才能达到我们现在的水平。我们将在美国和全球范围内履行所有承诺的剂量。”</blockquote></p><p> The White House and the Department of Health and Human Services did not respond to multiple requests for comment.</p><p><blockquote>白宫和卫生与公众服务部没有回应多次置评请求。</blockquote></p><p></p><p> But three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.</p><p><blockquote>但三位知情人士表示，他们不相信该公司拥有持续复制高质量疫苗所需的资源——Novavax在此之前必须达到的基准。这些人表示，Novavax可能会解决其制造问题，并在2022年底前获得全面许可。</blockquote></p><p> Novavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.</p><p><blockquote>Novavax以前从未生产过疫苗，拒绝回答有关其产品纯度水平以及是否成功解决了长期存在的生产问题的具体问题。</blockquote></p><p> Unlike <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.</p><p><blockquote>不像<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>Moderna是第一家使用快速产生的信使RNA推出疫苗的制造商，Novavax正在采用以前使用但复杂的方法，即用细菌细胞制造关键成分。虽然科学家们对感染细胞产生刺突蛋白的过程很熟悉，但很难扩大规模。</blockquote></p><p> The revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.</p><p><blockquote>Novavax持续存在的生产问题被曝光之际，世界上只有36%的人接种了疫苗，而且发展中国家的领导人继续向美国施压，要求其提供更多剂量。仅在非洲，只有4.4%的人口接种了疫苗。</blockquote></p><p> That includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.</p><p><blockquote>这包括非洲大陆一些人口最多的国家，如尼日利亚和乌干达，这些国家约有1%的公民完全接种了疫苗。</blockquote></p><p> Novavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson &amp; Johnsonhalted work at a Baltimore facilityrun by contract manufacturer <a href=\"https://laohu8.com/S/EBS\">Emergent BioSolutions</a> after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.</p><p><blockquote>Novavax只是最新一家在承诺成为发展中国家主要疫苗供应商后遇到核心生产问题的疫苗制造商。四月，强生公司停止了巴尔的摩一家由合同制造商运营的工厂的工作<a href=\"https://laohu8.com/S/EBS\">新兴生物解决方案</a>在发现1500万剂疫苗意外被另一种Covid-19疫苗的成分污染后。</blockquote></p><p> J&amp;J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.</p><p><blockquote>根据联合国儿童基金会保存的记录，强生公司的生产流程恢复缓慢，迄今为止，该公司仅生产了最初承诺在年底前向COVAX生产的2亿剂疫苗的一小部分。</blockquote></p><p> “Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”</p><p><blockquote>国际倡导组织Health GAP的执行董事亚洲·拉塞尔(Asia Russell)表示：“承诺过多而兑现不足是这些制造商的游戏名称。”“这就是全球应对措施的基础设施，这太可怕了。”</blockquote></p><p> Unlike Johnson &amp; Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.</p><p><blockquote>与强生不同，Novavax是疫苗界的新手。它从未成功推出过疫苗，并且在大流行之前一直在财务上苦苦挣扎。在经历了一系列药物开发失败后，该公司于2019年出售了其生产设施，这笔交易还包括解雇100名员工。当年5月，Novavax股价曾一度跌至每股36美分。</blockquote></p><p> Yet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.</p><p><blockquote>然而，随着Covid-19的出现，该公司的命运发生了变化。在大流行初期争相开发一系列候选疫苗的过程中，特朗普政府向Novavax提供了16亿美元，以帮助其开发Covid-19疫苗——这是当时向所有Covid-19疫苗制造商提供的最大一笔交易。</blockquote></p><p> The contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.</p><p><blockquote>该合同代表了对Novavax能力的重大信任票，在后期试验显示该疫苗对病毒的有效性为90%后，这一赌注似乎得到了回报。</blockquote></p><p> But even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.</p><p><blockquote>但两名直接了解这些讨论的人士表示，即便如此，负责加速疫苗开发的“曲速行动”（Operation Warp Speed）的特朗普政府高级官员也一再警告该公司，在扩大疫苗生产规模时可能会遇到问题。</blockquote></p><p> In particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.</p><p><blockquote>他们特别担心，一旦疫苗投入大规模生产，Novavax将难以确保疫苗始终符合FDA严格的质量标准——这正是困扰该公司数月的问题。</blockquote></p><p> “They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”</p><p><blockquote>“他们仓促行事，”一位知情人士说。“这很难做到。而且他们也做不到。”</blockquote></p><p> Taylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.</p><p><blockquote>Novavax发言人泰勒在一份声明中表示，该公司已纳入监管机构的反馈，并“在扩大我们的商业制造流程方面取得了巨大进展”。她说，该公司仍有望在今年年底前每月生产1.5亿剂疫苗，并在美国和国际监管机构备案之前储备了数千万剂疫苗。</blockquote></p><p> Company executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.</p><p><blockquote>公司高管在最近给投资者的演讲中也表现出了类似的乐观语气，淡化了制造障碍，并预测很快就会获得批准，开始分发剂量。在aSept期间。29日投资者活动，首席商务官John Trizzino表示，该公司已经“解决”了问题，并接近提交最终监管申请。</blockquote></p><p> “We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”</p><p><blockquote>Novavax研发总裁格雷戈里·格伦(Gregory Glenn)在谈到其疫苗批次时补充道：“我们现在确实在测试我们的批次。”“我们认为这很快就会结束。”</blockquote></p><p></p><p> U.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&amp;J’s vaccine at the Emergent plant earlier this year, those people said.</p><p><blockquote>据三位知情人士透露，与该公司合作的美国官员没有那么自信。这些人士表示，Novavax的制造问题被认为比今年早些时候导致强生在Emergent工厂停止生产疫苗的卫生和设计问题更难解决。</blockquote></p><p> And even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.</p><p><blockquote>尽管该公司开始在其他国家寻求监管部门的批准，但美国仍怀疑该公司是否解决了根本的疫苗纯度缺陷，知情人士称，这些缺陷影响了该公司在世界各地工厂生产疫苗的能力。</blockquote></p><p> Several vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.</p><p><blockquote>几批疫苗已经被丢弃，四名知情人士表示，美国官员现在预计该公司最早要到明年才能获得FDA对疫苗的批准。</blockquote></p><p> “At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”</p><p><blockquote>“在某种程度上，我认为功效永远不会超过与其中杂质相关的风险，”一位知情人士说。“我并不惊讶我们会在这里。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174375951","content_text":"(Oct 20)  Novavax may delay the delivery of 1 billion doses of coronavirus vaccine because of the production problems.\nThe world’s vaccine distributor has been counting on U.S. companies to provide more than 2 billion doses to lower and middle-income countries by the end of 2022 — a crucial step in ending the Covid-19 pandemic.\nBut the campaign run by the international consortium known as COVAX, which has already been delayed significantly because of production lags, is now likely to fall short by more than 1 billion doses as a key supplier faces significant hurdles in proving it can manufacture a shot that meets regulators’ quality standards, according to three people with direct knowledge of the company’s problems.\nThe delay, which was confirmed by three other people familiar with the discussions between Maryland-based Novavax and the Biden administration, represents a major setback in the effort to vaccinate the world in the wake of new, more transmissible variants.\nThe U.S. government invested $1.6 billion in Novavax in 2020 — the most it devoted to any vaccine maker at the time — in hopes that it would offer the world another option for a safe and effective vaccine to help protect against Covid-19. But the company has consistently run into production problems. The methods it used to test the purity of the vaccine have fallen short of regulators’ standards and the company has not been able to prove that it can produce a shot that is consistently up to snuff, according to multiple people familiar with Novavax’s difficulties. All spoke on the condition of anonymity to discuss sensitive company conversations.\nAlthough Novavax recently attested to some of its analytics and testing issues in aquarterly filing with the Securities and Exchange Commission, the company’s issues are more concerning than previously understood, according to two of the people with direct knowledge of the matter.\nThe Food and Drug Administration works out purity levels with each manufacturer according to June 2020 guidance for coronavirus vaccines, but it is generally understood that each vaccine batch should reach at least 90 percent. The company has struggled to attain anywhere close to that, one of the people with direct knowledge of the situation said. Another person familiar with the company’s manufacturing process said Novavax has recently shown purity levels hovering around 70 percent. Low purity levels increase the chance that contaminants or unnecessary substances are in the final product, rendering the vaccine less effective or introducing the chance that patients could react to unknown ingredients.\nCOVAX, which recently downgraded its 2021 goal from 2 billion to 1.425 billion doses, has already estimated that it faces a supply shortfall of as many as 1 billion doses in its effort to vaccinate the developing world. If Novavax falters, it could double the deficit through 2022, leaving hundreds of millions of people without immunity against Covid-19 and extending the pandemic.\n“COVAX continues to be challenged for adequate supply … in that context, Novavax’s manufacturing challenges and delays have been massively disruptive,” said Krishna Udayakumar, director of the Duke Global Health Innovation Center.\nThe global coalition is already behind on hundreds of millions of planned doses this month, having shipped just 371 million of its 700 million dose target for October. It is now also at risk of missing its already downgraded 2021 target.\nBetween Novavax and other manufacturers’ hurdles, “COVAX has had to scramble to revise its supply strategy significantly in real time,” Udayakumar said. As a result, global health groups are emphasizing more donations to cover immediate needs, he added.\nIn a statement, Novavax Senior Vice President of Investor Relations and Corporate Affairs Silvia Taylor told POLITICO that the company’s analytical testing methods have been “validated” — but did not answer questions about whether the FDA had signed off on them. The company still plans on filing an emergency use authorization by the end of the year, Taylor said.\n“The vaccine development and regulatory submission processes are highly complex and often require years to advance to the point where we are now. We will fulfill all of our committed doses both in the US and globally,” Taylor said.\nThe White House and the Department of Health and Human Services did not respond to multiple requests for comment.\nBut three people familiar with the matter said they are not confident that the company has the resources needed to reproduce a high-quality vaccine on a consistent basis — a benchmark Novavax must meet before that time. Those same people said Novavax could potentially fix its manufacturing issues and reach full licensure by the end of 2022.\nNovavax — which has never produced a vaccine before — declined to answer specific questions about its product’s purity levels and whether it had been successful in addressing its longstanding manufacturing issues.\nUnlike Pfizer and Moderna, the first manufacturers to launch vaccines using rapidly produced messenger RNA, Novavax is employing the previously used but complicated approach of creating the key ingredient with bug cells. While the process, which involves infecting the cells to produce spike proteins, is familiar to scientists, it is difficult to scale.\nThe revelations about Novavax’s continued manufacturing problems come at a time when only 36 percent of the world is vaccinated and as leaders of developing nations continue to pressure the U.S. to deliver more doses. In Africa alone, only 4.4 percent of the population is vaccinated.\nThat includes some of the continent’s most populous nations, like Nigeria and Uganda, where about 1 percent of citizens are fully vaccinated.\nNovavax is just the latest vaccine maker to run into core production problems after promising to serve as a major vaccine contributor to the developing world. In April, Johnson & Johnsonhalted work at a Baltimore facilityrun by contract manufacturer Emergent BioSolutions after it found that 15 million doses had been accidentally contaminated with ingredients from a separate Covid-19 vaccine.\nJ&J’s manufacturing process has been slow to recover, and to date it has produced just a fraction of the 200 million shots it initially pledged to COVAX by the end of the year, according to records kept by UNICEF.\n“Overpromising and underdelivering is the name of the game for these manufacturers,” said Asia Russell, executive director of international advocacy group Health GAP. “And that’s the infrastructure of the global response, which is terrifying.”\nUnlike Johnson & Johnson, Novavax is a novice in the vaccine world. It has never successfully launched a vaccine, and had struggled financially prior to the pandemic. After a string of drug development failures, it sold its manufacturing facilities in 2019 — a deal that also included parting with 100 employees. In May of that year, Novavax’s stock price dropped as low as 36 cents per share.\nYet the company’s fortunes shifted as Covid-19 took hold. Amid a scramble early in the pandemic to develop a range of vaccine candidates, the Trump administration awarded Novavax $1.6 billion to aid work on its Covid-19 shot — the largest deal given to any Covid-19 vaccine maker at that time.\nThe contract represented a major vote of confidence in Novavax’s capabilities — and a bet that appeared to pay off after late-stage trials showed the vaccine was 90 percent effective against the virus.\nBut even then, senior Trump administration officials on Operation Warp Speed — a group tasked with accelerating vaccine development — repeatedly warned the company that it risked running into problems in scaling up manufacturing of the shot, two people with direct knowledge of those discussions said.\nIn particular, they worried that Novavax would have difficulty ensuring that the vaccine consistently met the FDA’s rigorous quality standards once the vaccine went into mass production — the exact problem that has now stymied the company for months.\n“They rushed the process,” one of the people with knowledge of the matter said. “It’s hard to make. And they can’t make it.”\nTaylor, the Novavax spokesperson, said in a statement that it has incorporated feedback from regulators and has made “tremendous progress with the scale-up of our commercial manufacturing processes.” The company is still on track to produce 150 million doses a month by the end of the year, she said, and has stockpiled tens of millions of doses ahead of regulatory filings in the U.S. and internationally.\nCompany executives in recent presentations to investors have struck a similarly optimistic tone, downplaying the manufacturing snags and predicting it will soon be cleared to begin distributing doses. During aSept. 29 investor event, Chief Commercial Officer John Trizzino said the company had “resolved” its problems and was close to submitting a final regulatory application.\n“We’re really moving along with testing our lots now,” added Gregory Glenn, president of Novavax’s research and development, referring to batches of its vaccine. “We think that this is shortly going to come to a close.”\nU.S. officials working with the company are not as confident, according to three people with knowledge of the matter. Novavax’s manufacturing problems are seen as far more difficult to fix than the sanitary and design concerns that halted production of J&J’s vaccine at the Emergent plant earlier this year, those people said.\nAnd even as the company begins to seek regulatory approval in other countries, there remains doubt in the U.S. that it has solved the fundamental vaccine purity flaws that the people with knowledge said have affected its ability to make doses at plants around the world.\nSeveral vaccine batches have already been discarded, and four people with knowledge of the matter say U.S. officials now no longer expect the company to win FDA sign-off on the vaccine until next year at the earliest.\n“At some level, I think the efficacy was never going to outweigh the risk associated with the impurity that was in there,” said one of the people with knowledge of the matter. “I’m not surprised this is where we are.”","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603619690,"gmtCreate":1638404643257,"gmtModify":1638404643467,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Not the time yet","listText":"Not the time yet","text":"Not the time yet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603619690","repostId":"2188690505","repostType":4,"isVote":1,"tweetType":1,"viewCount":3551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850281587,"gmtCreate":1634602242348,"gmtModify":1634602242420,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"Very good","listText":"Very good","text":"Very good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850281587","repostId":"1114416896","repostType":4,"isVote":1,"tweetType":1,"viewCount":2414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829404697,"gmtCreate":1633530962458,"gmtModify":1633530962530,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"why sell???","listText":"why sell???","text":"why sell???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829404697","repostId":"1126696993","repostType":2,"isVote":1,"tweetType":1,"viewCount":2329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606853487,"gmtCreate":1638861086065,"gmtModify":1638861086179,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"EV to the moon","listText":"EV to the moon","text":"EV to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606853487","repostId":"2189682681","repostType":4,"isVote":1,"tweetType":1,"viewCount":3396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":851838102,"gmtCreate":1634890474595,"gmtModify":1634890474595,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMD\">$AMD(AMD)$</a>&nbsp;up up up!!!&nbsp;","text":"$AMD(AMD)$ up up up!!!","images":[{"img":"https://static.tigerbbs.com/2da1478496dda3d23161f71934bb6c2b","width":"1080","height":"2375"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/851838102","isVote":1,"tweetType":1,"viewCount":2301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":839362705,"gmtCreate":1629122847907,"gmtModify":1633687233567,"author":{"id":"3581131361771943","authorId":"3581131361771943","name":"Frostyyy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581131361771943","authorIdStr":"3581131361771943"},"themes":[],"htmlText":"loving the reds","listText":"loving the reds","text":"loving the reds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839362705","repostId":"1133200546","repostType":4,"isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}